Evaluation of Risk Versus Benefit Information in Direct-To-Consumer (DTC) Prescription Drug Television Advertisements

Overview of attention for article published in Therapeutic Innovation & Regulatory Science, December 2018

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (52nd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

Readers on

mendeley: 19 Mendeley

So far, Altmetric has seen 7 X posts from 4 X users, with an upper bound of 6,363 followers.

Read Dr. Barone's article in Sage Journals titled, Evaluation of Risk Versus Benefit Information in Direct-To-Consumer (DTC) Prescription Drug Television Advertisements: https://t.co/iwRqkMlnS0

Evaluation of Risk Versus Benefit Information in DTC Rx Drug TV Ads | Therapeutic Innovation & Regulatory Science - Germin Fahim, Michael Toscani, Joseph A. Barone, Chris Wang, Shivani Gandhi, 2018 https://t.co/G7ogS9cKP1

"Evaluation of Risk vs Benefit Information in Direct-To-Consumer (DTC) Prescription #Drug Television Advertisements," Therapeutic Innovation & Regulatory Science https://t.co/oY9z069ev3

RT @PharmerRob: Evaluation of Risk vs Benefit Info in DTC Rx TV Ads - Therapeutic Innovation & Regulatory Science https://t.co/wGIPNowlE7

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 3 additional X posts.